References
- Raje N, Anderson K. Thalidomide – a revival story. New Engl J Med 1999;341:1606–1609.
- Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 1999;5:582–585.
- Uchiyama H, Barut BA, Mohrbacher AF, et al Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82:3712–3720.
- Chauhan D, Uchiyama H, Akbarali Y, et al Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996;87:1104–1112.
- Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3–21.
- Damiano JS, Cress AE, Hazlehurst LA, et al Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658–1667.
- Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996;31:213–221.
- Jakob C, Sterz J, Zavrski I, et al Angiogenesis in multiple myeloma. Eur J Cancer 2006;42:1581–1590.
- Field EO, Gibbs JE, Tucker DF, et al Effect of thalidomide on the graft versus host reaction. Nature 1996;211:1308–1310.
- Vogelsang GB, Farmer ER, Hess AD, et al Thalidomide for the treatment of chronic graft-versus-host disease. New Engl J Med 1992;326:1055–1058.
- Haslett PA, Corral LG, Albert M, et al Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187:1885–1892.
- Hayashi T, Hideshima T, Akiyama M, et al Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005;128:192–203.
- LeBlanc R, Hideshima T, Catley LP, et al Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103:1787–1790.
- Galustian C, Meyer B, Labarthe M-C, et al The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58:1033–1045.
- Brown RD, Yuen E, Nelson M, et al The prognostic significance of T cell receptor β gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia 1997;11:1313–1317.
- Raitakari M, Brown RD, Gibson J, et al T cells in myeloma. Hematol Oncol 2003;21:33–42.
- Sze DM-Y, Brown RD, Yuen E, et al Clonal cytotoxic T cells in myeloma. Leuk Lymphoma 2003;44:1667–1674.
- Spencer A, Prince M, Roberts AW, et al Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009;27:1788–1793.
- Liu W, Putnam AL, Xu-yu Z, et al CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Tregs. J Exp Med 2006;203:1701–1711.
- Davies FE, Raje N, Hideshima T, et al Thalidomide and immunomodulatory derivatives augment natural killer cytotoxicity in multiple myeloma. Blood 2001;98:210–216.